Images from the Yong lab
May 25, 2021
Researchers study Vitamin B3 as potential treatment for deadly brain tumour
A vitamin that is commonly used to fortify breakfast cereals is being studied by Cumming School (CSM) researchers for its potential to benefit people diagnosed with glioblastoma.
The study involving niacin — also known as Vitamin B3 — has the potential to boost the body’s immune system to fight the devastating brain tumour, but researchers must first complete a phase l-II clinical trial to determine the optimal dose and uncover any side effects.
“We want to know if it is safe, if it can be added to the standard treatment, and what dose should be used — that's phase l,” says neuro-oncologist Dr. Gloria Roldan Urgoiti, MD, a clinical associate professor at the CSM who is the principal investigator of this study. “You cannot assume that, because it is something that is available over the counter, you can just combine it with the standard treatment safely.”
Glioblastoma 'difficult to keep at bay'
After the safe dose is identified, and if the trial does not encounter unexpected toxicities, a total of 58 patients will be included in phase II to evaluate if it is effective to slow tumour growth.
The study, offered at the Tom Baker Cancer Centre in Calgary to adults up to age 75, addresses the most common malignant brain tumour in adults. Approximately 50 new glioblastoma cases are diagnosed each year in Calgary and 90 per cent are IDH-wildtype, which is the main molecular subtype and the focus of the study.
“The main problem with glioblastoma is that, although we have treatments to control it, we have difficulty keeping it at bay,” says Dr. Paula de Robles, MD, a clinical assistant professor at the CSM and a neuro-oncologist at the Foothills Medical Centre. “And in the majority of the patients, the tumour will come back eventually.”
After diagnosis, which typically follows the onset of neurological symptoms, standard of care treatment includes surgery followed by radiation therapy and oral chemotherapy. Even with aggressive treatment, in the majority of the cases the tumour returns within a year from diagnosis, says de Robles.
“That is why we are hoping we can make a difference with this clinical trial because we're giving niacin early, to try to help the standard of care.”
Tumours compromise immune system
Like many groundbreaking clinical trials, the niacin study has a long history that includes years of meticulous basic science research and investigators who chose to look at the problem from a new perspective.
Dr. V. Wee Yong, PhD, a professor and researcher at the CSM, says his group’s early paper on glioblastoma — published in the journal Nature Neuroscience in 2014 — recognized that the immune system is compromised by the tumours. Instead of suppressing the tumour growth, the immune system is subverted and used to the tumour's advantage.
“Glioblastoma stops the immune system that is trying to attack the tumour, and then it goes even further and exploits it for its own growth.”
It was also noted that a type of cell in the brain called microglia — the immune cells of the central nervous system — were not functioning properly.
Can vitamin B3 give immune system a boost?
Numerous drugs have been studied around the world to attack glioblastoma — all with little success. Instead, Yong decided to look for a stimulator of microglia in order to rejuvenate the compromised immune cells.
“We had already screened a library of 1,040 compounds and discovered some that suppress activity in microglia — which we then brought into our multiple sclerosis (MS) work — because that's what you want to do in MS.”
But for glioblastoma, he wanted the complete opposite — a drug that would give the immune system a boost and let it battle the tumour like it was meant to do.
“And that was niacin — Vitamin B3,” he says.
Next step: clinical trial
Over a span of five years, his team, led by research associate Dr. Susobhan Sarkar, PhD, showed that when compromised microglia are treated with niacin these microglia could stop the growth of the glioblastoma stem cells in culture. The team then moved the research to mice.
“Most impressively, when mice harboring intracranial glioblastoma were treated with niacin together with temozolomide (which is the standard chemotherapy for glioblastoma) they had a very prolonged survival.”
But before the bench research (published in Science Translational Medicine in 2020) can be translated to bedside care, a clinical trial is required to test if the vitamin is safe in patients with glioblastoma and to study how the body reacts to it.
“I first engaged Dr. Paula de Robles, who then introduced me to Dr. Gloria Roldan Urgoiti — and those are my two clinical collaborators,” recalls Yong.
The trio started enrolling their first study participants in April.
“Many clinical trials that have been done in patients with glioblastoma, but unfortunately most have failed to show increased survival,” says de Robles.
So we always get excited when there's a new thing. People living with this diagnosis are excited, too.
Images from the Yong lab
Power of collaboration
In this phase l-II study, all participants will receive the drug concurrently to the standard of care. And though niacin has been used therapeutically in the past for the treatment of cholesterol, there are many unanswered questions that must be addressed before the research team can begin to measure the drug’s effect on the tumour.
“Can I tell you what will be the dose that they will tolerate? No,” says Roldan Urgoiti. “Can I tell you what is an effective dose? No — those are the answers that we hope the trial will give us.”
The entire project has been a testament to the power of collaboration between basic scientists and clinicians — and between members of different departments and institutes at the University of Calgary.
“Scientists alone can only take things so far,” says Yong. “We may have great ideas and great results published in top journals, but if you don't go on to show that it impacts humans, it is just another nice paper.”
Echoes Roldan Urgoiti: “This kind of research — which goes from the lab to the patient — is possible because we are in Calgary and we are in the University of Calgary. We have a very close relationship between the Charbonneau Institute, the Hotchkiss Brain Institute, and all the research areas.”
If the phase l trial is successful, phase ll will follow on to measure the effect of niacin on extending survival of patients with glioblastoma.
“There is always hope,” says Roldan Urgoiti. “We know it's a disease that we cannot cure, but we can always try to improve someone’s quality of life and help them live as long as possible.”
This Phase I/II study is supported by a foundation grant from the Canadian Institutes of Health Research, a gift from the Kvisle Fund through the Alberta Cancer Foundation, and developed with the support of the Clinical Research Unit at the Tom Baker Cancer Centre, Alberta Health Services.
Gloria Roldan Urgoiti is a clinical associate professor in the Department of Oncology at the CSM and a member of the Hotchkiss Brain Institute and the Arnie Charbonneau Cancer Institute.
Paula de Robles is a clinical assistant professor in the departments of Clinical Neurosciences and Oncology at the CSM and leader of the Tom Baker Cancer Centre Neuro-Oncology Program.
V. Wee Yong is a professor in the departments of Clinical Neurosciences and Oncology at the CSM and a member of the Hotchkiss Brain Institute and Arnie Charbonneau Cancer Institute.